Generated by AI
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its principal product candidate, galinpepimut-S, is an immunotherapeutic designed to stimulate immune responses against Wilms tumor 1, a protein expressed across multiple tumor types. The company also develops SLS009, a selective cyclin-dependent kinase 9 inhibitor intended to address oncology applications through a distinct molecular mechanism. SELLAS concentrates on late-stage clinical development and therapeutic innovation in areas of significant unmet medical need, serving the pharmaceutical and biotechnology markets. Its work spans cancer immunotherapy, targeted drug development, clinical research, regulatory activities, and potential commercialization of oncology products. Headquartered in New York City, SELLAS occupies a specialized role within the life sciences sector by advancing investigational treatments designed to complement existing cancer-care approaches and broaden the range of therapeutic options available to patients and healthcare providers.
Website7 Times Square
New York, NY, 10036
United States
The latest articles about SLS.
The vaccine reduced risk of death for certain acute myeloid leukemia patients, according to drugmaker
Analyst rates Sellas Life Sciences a Sell: its roughly $4 billion valuation outstrips GPS's roughly $826 million risk-adjusted U.S.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 19's posts. Generated by AI.
Investors talking about SLS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.